MAPT and frontotemporal dementia: QC-01-175 with a tau ligand (18F-T807 derivative) and a CRBN ligand (Figure 9) degraded aberrant tau in frontotemporal dementia (FTD) patient-derived neuronal cell models in in vitro assay [30].